venBio Partners

General contacts

Investor type

Founded

2011

AUM

$2 000 M

Location

San Francisco, California, United States

Investment Ticket

$10-50 m

Investment Stage

Series A Seed Series B Late Stage (Series C+)

Region of investment

North America Europe

ESG Focus

Impact investor

Investor profile last updated: 16 August, 2026

Profile

venBio Partners is a venture capital firm based in San Francisco, founded in 2011 by Corey Goodman and Robert Adelman. The firm focuses on life sciences, specifically aiming to partner with industry leaders to develop game-changing medicines and technologies. The team includes experienced professionals like Corey Goodman, Aaron Royston, and Richard Gaster, who bring a wealth of knowledge in various scientific and investment disciplines. venBio distinguishes itself through a strong focus on unmet medical needs and a strategy aligned with potential acquisition partners from the outset.

The firm invests in the life sciences sector, with an emphasis on novel therapeutics for unmet medical needs. Their venture funds comprise nearly $2 billion in committed capital. venBio's investment stages typically span Series A through late-stage opportunities. While based in North America, their geographic investment focus is global due to the nature of biotech innovation.

Notable portfolio companies include Vicebio, a next-generation vaccine biotech acquired by Sanofi for $1.6 billion, and Candid Therapeutics, recognized as a 2025 Endpoints 11 Honoree. VenBio works closely with its portfolio to navigate clinical trial design, regulatory considerations, and overall development strategy.

Industry

Healthcare Services HealthTech Biotechnology Pharmaceuticals MedTech Life Sciences Digital Medical Devices Technology

venBio Partners Funds

Name	Type	Industry	Stage	Region	Size	AUM	Launch date
venBio Global Strategic Fund, L.P.	Venture Capital (VC)	Pharmaceuticals Life Sciences	Pre-seed Seed	North America	$5-10 m	$177 M	November 2010
venBio Global Strategic Fund II	Venture Capital (VC)	Pharmaceuticals Life Sciences	Pre-seed Seed	North America South America Europe Middle East Africa Asia Australia and others	$5-10 m	$315 M	May 2016
venBio Global Strategic Fund III	Venture Capital (VC)	Pharmaceuticals Life Sciences	Pre-seed Seed Series A	North America	$5-10 m	$394 M	April 2020
venBio Global Strategic Fund IV, LP	Venture Capital (VC)	Pharmaceuticals Life Sciences	Pre-seed Seed	North America	$5-10 m	$550 M	June 2021

Contacts

Name

Title

Social Networks

Richard Gaster, M.D., Ph.D. Managing Partner

Managing Partner

r•••@•••

Aaron Royston, M.D. Managing Partner

Managing Partner

a•••@•••

Upgrade to see contacts

2bqAsu8gpev3kdaR 2bqAsu8gpev3kdaR

2bqAsu8gpev3kdaR

[email protected]

2bqAsu8gpev3kdaR 2bqAsu8gpev3kdaR

2bqAsu8gpev3kdaR

[email protected]

2bqAsu8gpev3kdaR 2bqAsu8gpev3kdaR

2bqAsu8gpev3kdaR

[email protected]

Investment-team contacts for venBio Partners — including verified work emails and LinkedIn profiles — are available to Private Equity List subscribers.
Instant access on the web. Plans from $129/month — see pricing.

Contacts sourced from the firm's website and LinkedIn, re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

FAQs about venBio Partners

Is venBio Partners a venture capital or private equity firm?

venBio Partners is a venture capital firm. It backs companies at Series A, Seed, Series B and Late Stage (Series C+), writing tickets of $10-50 m.

Where is venBio Partners located?

venBio Partners is located in San Francisco, California, United States.

When was venBio Partners founded?

venBio Partners was founded in 2011.

What sectors and industries does venBio Partners invest in?

venBio Partners invests in companies and startups in Healthcare Services, HealthTech, Biotechnology, Pharmaceuticals, MedTech, Life Sciences, Digital, Medical Devices, Technology.

What is venBio Partners geographical focus of investments?

venBio Partners invests in companies and startups in North America, Europe.

At what stages of companies and startups does venBio Partners typically invest in?

venBio Partners invests in companies and startups at Series A, Seed, Series B, Late Stage (Series C+).

What is the usual amount of venBio Partners investment?

venBio Partners usually invests $10-50 m on average.

What is the amount of assets of under management (AUM) for venBio Partners?

venBio Partners has around $2 000m assets under management.

When was venBio Partners last fund created?

venBio Partners last fund was created/launched in 2021-06-25

Is venBio Partners impact investor?

Yes, venBio Partners is impact investor.

What are the contacts of venBio Partners?

venBio Partners can be reached through its website venbio.com and its LinkedIn page. Its general enquiries address is [email protected]. Cold-mailing a general inbox rarely reaches a partner, so Private Equity List also lists the investment-team contacts for venBio Partners — names, roles, verified work emails and LinkedIn profiles — available on a Pro plan from $129/month (see pricing). Contacts are sourced from the firm's website and LinkedIn and re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

Can I access venBio Partners data via API or MCP?

Yes. Every field on this page — profile, funds, investment criteria, portfolio and investment-team contacts — is available programmatically through the Private Equity List REST API and MCP server, so AI assistants such as Claude and ChatGPT can query venBio Partners directly instead of scraping this page. One subscription covers both the web app and machine access — see API & MCP.

When was the venBio Partners profile last updated?

Private Equity List re-verifies investor profiles on a rolling cycle, pulling from the firm's own website and LinkedIn rather than a one-off import. This profile was last updated on 16 August, 2026. Something out of date here? Report it — we re-run that firm within 48h and get back to you.